Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
192 participants
INTERVENTIONAL
2003-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Use of Naltrexone in a Clinical Setting
NCT00000445
Naltrexone for Relapse Prevention
NCT00000442
Post-Treatment Effects of Naltrexone
NCT00006449
Naltrexone for Early Problem Drinkers
NCT00000455
Naltrexone Maintenance Treatment of Alcoholism
NCT00000450
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
TREATMENT
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
naltrexone (Revia)
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Committed to alcohol abstinence as a treatment goal.
* Individuals will be required to identify two family members or close friends who are knowledgeable about their location, drinking behavior, and psychosocial status.
Exclusion Criteria
* Meets criteria for a major psychiatric disorder and are in need of or currently undergoing pharmacotherapy.
* Females who are pregnant, lactating, or not using a reliable method of contraception.
* Currently experiencing a serious medical condition that would place them at risk or interfere with study participation.
* Experiencing acute hepatitis or liver failure or whose liver function test is more than 3 times normal.
* Have a history of severe allergies, multiple adverse drug reactions or known allergy to naltrexone.
* Vocabulary below the 5th grade reading level.
* Abnormal MRI scan.
* HIV infection due to the neurological sequelae.
* Significant central nervous system diseases.
* Seizure disorder or history of closed head trauma.
* Neuroendocrine disorders.
* Treatment with opiates within the last six months.
30 Years
55 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
NIH
Johns Hopkins University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Johns Hopkins University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Johns Hopkins Hospital
Baltimore, Maryland, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NIAAAMCC11855
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.